aldehyde dehydrogenase 2 family memberGenealiases: ALDH-E2 · ALDHI · ALDM
Q-omics provides the consensus-scored ALDH2 profile across patient tissues and cancer cell-line models. ALDH2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ALDH2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ALDH2 protein abundance shows 25,537 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where ALDH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALDH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALDH2 survival associations across molecular data types. ALDH2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALDH2 RNA expression–survival associations across cancer types. High ALDH2 expression shows favorable associations in KIRP, MESO, BRCA, KICH, COAD and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ALDH2 RNA expression.
This table summarizes ALDH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ALDH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALDH2 shows lower tumor expression in BLCA, KICH, THCA, HNSC, LUSC and LUAD. The BLCA box plot shows higher ALDH2 RNA expression in normal versus tumor tissue (log2 FC = −3.687, t-test p < 0.001).
This table shows molecular features associated with ALDH2 in patient tissues and cancer cell lines. In patient samples, ALDH2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALDH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
